Bacteria were first detected in human tumors more than 100 years ago, but the characterization
of the tumor microbiome has remained challenging because of its low biomass. We …

Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers
of a wide range of histologies. Broadening the clinical applicability of these treatments …

Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy.
Until now, predictive biomarkers 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10 and strategies to augment …

Checkpoint blockade therapies that reactivate tumour-associated T cells can induce durable
tumour control and result in the long-term survival of patients with advanced cancers 1 . …

Treatment of cancer has been revolutionized by immune checkpoint blockade therapies.
Despite the high rate of response in advanced melanoma, the majority of patients succumb to …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and immune-…

Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found
in 50–70% of malignant melanomas 1 . Pre-clinical studies have demonstrated that the B-…

Drug resistance presents a challenge to the treatment of cancer patients. Many studies have
focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that …

The gut microbiome has been shown to influence the response of tumors to anti–PD-1 (programmed
cell death–1) immunotherapy in preclinical mouse models and observational …

Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes 1 , 2 . The clinical presentation of patients with different subtypes is often …